skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Aliskiren in hypertension: evidence for its potential therapeutic value

Review

(2619) Views  (874) Full article downloads

Authors: Doris Peter

Published Date March 2005 Volume 2005:1-Issues 1 & 2(1) Pages 0 - 0
DOI: http://dx.doi.org/10.2147/CE.S6403

Doris Peter

Core Medical Publishing, 445 Hamilton Avenue, Suite 1102, White Plains, New York, NY 10601, USA

Introduction: Aliskiren is the first in a new class of antihypertensive drugs that inhibits the conversion of angiotensinogen to angiotensin I by renin, thereby inhibiting production of angiotensin II, the key mediator in the regulation of body fluid volume and blood pressure. Aliskiren is currently in phase III trials as monotherapy and phase II as combination therapy in patients with mild-to-moderate hypertension, and in phase II trials in patients with diabetic nephropathy.

Aims: The aim of this review is to evaluate the emerging evidence for use of aliskiren in patients with hypertension and to predict its preliminary place in therapy in clinical outcome terms. All randomized, controlled clinical trials of aliskiren (evidence level 2) were included for analysis of efficacy with the selected outcomes of blood pressure lowering, tolerability, and adherence; all other publications were excluded.

Evidence review: The available level 2 evidence, although limited to phase II trials, suggests that aliskiren is effective at lowering blood pressure, an accepted surrogate outcome of morbidity and mortality, in patients with mild-to-moderate uncomplicated essential hypertension. Preliminary evidence suggests aliskiren is as effective as the angiotensin receptor blocker irbesartan, but more studies are needed. The available evidence also suggests that aliskiren is well tolerated and that patients exhibit good adherence to therapy. Aliskiren’s effect on outcomes such as all-cause mortality, reduction in cardiovascular mortality, and reduction in cardiovascular events in patients with mild-to-moderate essential hypertension as well as in special patient populations, remains to be determined.

Clinical potential: The evidence available regarding aliskiren’s effect on outcomes, including blood pressure, tolerability, and adherence, supports its use in patients with mild-to-moderate hypertension. Although there is some preliminary evidence from small pilot trials, the use of aliskiren in combination with other antihypertensives, and the use of aliskiren in other patient populations, cannot be recommended without further evidence.

Key words: aliskiren, hypertension, outcomes, evidence, renin, diabetic nephropathy






 

Other articles by Dr Core Journal

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
Aripiprazole: the evidence of its therapeutic impact in schizophrenia
Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer
Bortezomib: the evidence of its clinical impact in multiple myeloma
Ciclesonide in persistent asthma: the evidence of its therapeutic value
Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes
Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia
Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia
Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction
Etanercept in psoriasis: the evidence of its therapeutic impact
Exubera® (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes
Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes
FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value
K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome
Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis
Maraviroc: the evidence for its potential in the management of HIV
Perindopril: the evidence of its therapeutic impact in hypertension
Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome
Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value
Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections
Topiramate: the evidence for its therapeutic value in the prevention of migraine
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus


Readers of this article also read:

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
Assessment and management of nutrition in older people and its importance to health
The role of herpesviruses in ocular infections
Reporting of results of interventional studies by the information service of the National Institutes of Health
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Analgesic efficacy of oral gabapentin added to standard epidural corticosteroids in patients with failed back surgery
Using systematically observed clinical encounters (SOCEs) to assess medical students’ skills in clinical settings
Erratum
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University